Quintet Private Bank Europe S.A. Makes New $26,000 Investment in Incyte Co. (NASDAQ:INCY)

Quintet Private Bank Europe S.A. acquired a new position in shares of Incyte Co. (NASDAQ:INCY) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 370 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

Several other institutional investors have also recently made changes to their positions in the company. CWA Asset Management Group LLC bought a new position in Incyte during the fourth quarter valued at about $1,933,000. Orion Portfolio Solutions LLC purchased a new stake in Incyte during the third quarter valued at about $770,000. Greenwood Capital Associates LLC purchased a new stake in Incyte during the third quarter valued at about $433,000. Tri Ri Asset Management Corp purchased a new stake in Incyte during the third quarter valued at about $3,292,000. Finally, Cypress Capital Group purchased a new stake in Incyte during the third quarter valued at about $971,000. Institutional investors own 96.97% of the company’s stock.

Insider Buying and Selling

In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of the business’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the transaction, the executive vice president now owns 25,848 shares of the company’s stock, valued at approximately $1,914,561.36. The trade was a 35.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Thomas Tray sold 650 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $70.64, for a total value of $45,916.00. Following the completion of the transaction, the insider now directly owns 23,962 shares in the company, valued at approximately $1,692,675.68. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,721 shares of company stock worth $2,030,925. 17.60% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on INCY. Royal Bank of Canada lowered their price target on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a report on Tuesday, February 11th. JMP Securities reaffirmed a “market perform” rating on shares of Incyte in a research note on Tuesday, February 11th. StockNews.com downgraded shares of Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. William Blair reaffirmed an “outperform” rating on shares of Incyte in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $75.25.

Incyte Trading Down 4.4 %

Incyte stock opened at $70.26 on Tuesday. Incyte Co. has a 52 week low of $50.35 and a 52 week high of $83.95. The company has a market capitalization of $13.60 billion, a price-to-earnings ratio of 260.23, a price-to-earnings-growth ratio of 0.41 and a beta of 0.70. The stock has a 50-day moving average price of $71.78 and a 200 day moving average price of $70.02. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. Sell-side analysts anticipate that Incyte Co. will post 4.86 EPS for the current year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.